These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24835357)

  • 21. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
    Pulido F; Delgado R; Pérez-Valero I; González-García J; Miralles P; Arranz A; Hernando A; Arribas JR
    J Antimicrob Chemother; 2008 Jun; 61(6):1359-61. PubMed ID: 18343802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
    Guiguet M; Ghosn J; Duvivier C; Meynard JL; Gras G; Partisani M; Teicher E; Mahamat A; Rodenbourg F; Launay O; Costagliola D;
    AIDS; 2012 Nov; 26(18):2345-50. PubMed ID: 22695301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protease inhibitor monotherapy and the CNS: peace of mind?
    Perez-Valero I; Bayon C; Cambron I; Gonzalez A; Arribas JR
    J Antimicrob Chemother; 2011 Sep; 66(9):1954-62. PubMed ID: 21672918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
    AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.
    Fourati S; Flandre P; Calin R; Carcelain G; Soulie C; Lambert-Niclot S; Maiga A; Ait-Arkoub Z; Tubiana R; Valantin MA; Autran B; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Mar; 69(3):753-6. PubMed ID: 24187041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
    Sufka SA; Ferrari G; Gryszowka VE; Wrin T; Fiscus SA; Tomaras GD; Staats HF; Patel DD; Sempowski GD; Hellmann NS; Weinhold KJ; Hicks CB
    J Infect Dis; 2003 Apr; 187(7):1027-37. PubMed ID: 12660916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
    Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
    Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children.
    Pensieroso S; Romiti ML; Palma P; Castelli-Gattinara G; Bernardi S; Freda E; Rossi P; Cancrini C
    AIDS; 2006 Sep; 20(14):1893-6. PubMed ID: 16954733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection.
    Ripamonti D
    Evid Based Med; 2016 Oct; 21(5):184. PubMed ID: 27565944
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of baseline HIV viral load as a risk factor for loss of virologic suppression in protease inhibitor-based monotherapy trials.
    Papastamopoulos V; Baraboutis IG; Gerogiou O; Skoutelis AT
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):669; author reply 670. PubMed ID: 20335746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.